Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia

Phase 1 Completed 24 enrolled University Health Network, Toronto National Cancer Institute (NCI) · collab

Parallel-groupOpen-labelTreatment

Summary

RATIONALE: Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cytarabine and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving tipifarnib together with cytarabine and daunorubicin may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of tipifarnib when given with cytarabine and daunorubicin in treating older patients with acute myeloid leukemia.

Timeline

Start: 2007-04
Primary completion: 2010-03
Completion: —

Publications

Results Brandwein JM, Leber BF, Howson-Jan K, Schimmer AD, Schuh AC, Gupta V, Yee KW, Wright J, Moore M, MacAlpine K, Minden MD; NCI CTEP Protocol 6670. A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over. Leukemia. 2009 Apr;23(4):631-4. doi: 10.1038/leu.2008.341. Epub 2008 Dec 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	tipifarnib	Small molecule	200 mg	Oral
Subject	tipifarnib	Small molecule	300 mg	Oral
Subject	tipifarnib	Small molecule	400 mg	Oral
Subject	tipifarnib	Small molecule	600 mg	Oral
Background	Cytarabine	Small molecule	100 mg/m2	Intravenous
Background	Daunorubicin	Small molecule	60 mg/m2	Intravenous

Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia

Summary

Timeline

Publications

Drugs

Indications